Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693706 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
A Phase 1 study of Influenza, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00693706: Completed Phase 1 study of Influenza, sponsored by GlaxoSmithKline.
NCT00693706 is a Phase 1 study of Influenza that has completed, run by GlaxoSmithKline. The registered enrollment target is 200 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00693706, a Phase 1 study of Influenza, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to compare the safety of \& immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine \[Fluarix\] in healthy adults.
Primary Outcome
Solicited local symptoms were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity.
Conditions Studied
Interventions
- BIOLOGICAL Trivalent influenza vaccine GSK 138842A
- BIOLOGICAL Fluarix
Study Locations (2)
Florida
- GSK Investigational Site - Miami
Kansas
- GSK Investigational Site - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-06-02 |
| Est. Completion | 2009-03-26 |
| Phase | Phase 1 |
What the finished NCT00693706 record still lists
NCT00693706 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Trivalent influenza vaccine GSK 138842A is the first listed.
NCT00693706 reports a single indexed study location in Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT00693706 about?
NCT00693706 is a clinical study titled "Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix". The purpose of the study is to compare the safety of \& immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine \[Fluarix\] in healthy adults.
What is the current status of trial NCT00693706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2008-06-02. Estimated completion is 2009-03-26.
What conditions does trial NCT00693706 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00693706?
The interventions under investigation include: Trivalent influenza vaccine GSK 138842A (BIOLOGICAL), Fluarix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00693706?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00693706 being conducted?
This trial has 2 study locations across Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00693706's enrollment target sits among peer trials
200 83rd of 156 higher than 74 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI